ArticleResearch and practice in thrombosis and haemostasis2025
Probing rare von Willebrand disease-causing mutations in the D4 and C-domains of von Willebrand factor.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: von Willebrand disease (VWD) is characterized by absence or reduction of plasma von Willebrand factor (VWF) levels or reduced protein function. While the spectrum of causative VWD mutations is vast, there has been limited characterization of variants occurring within the D4-C6 domains of VWF that comprise the C-terminal portion of the molecule. Objectives: In this study, we investigated the impact of 9 putative low-frequency VWD-causing variants on VWF function. Methods: Variants were generated by site-directed mutagenesis and expressed in human embryonic kidney (HEK)293(T) cells and analyzed for expression, intracellular storage, and multimeric profile. The ability of Arg2379Cys to form dimers was assessed using an A2-CK fragment of VWF. Results: Arg2379Cys, Ser2497Pro, and Cys2639Tyr had significantly reduced secretion from HEK293T cells, while the other mutations all failed to be secreted. While cotransfection with wild-type VWF appeared to rescue expression, cotransfection with a deletion A1 construct demonstrated that only the Gly2044Asp, Glu2343Val, Ser2497Pro, and Cys2693Tyr variants could be rescued. All the variants failed to form appreciable pseudo-Weibel-Palade bodies in HEK293 cells and showed abnormal multimers in cell lysates. The Arg2379Cys variant could be overexpressed by only formed monomers and some dimers. Analysis with a VWF-A2CK protein demonstrated that in the homozygous state Arg2379Cys behaves likes a type 2A variant, while it is likely to be a type 1 variant in the heterozygous state. Conclusion: These data show that variants within the C-terminal region of VWF can dramatically impact proper VWF expression and can different impacts on VWF depending on homozygosity or heterozygosity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.